Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma.
10.3857/roj.2014.32.3.163
- Author:
Da Hoon JUNG
1
;
Mi Sook KIM
;
Chul Koo CHO
;
Hyung Jun YOO
;
Won Il JANG
;
Young Seok SEO
;
Eun Kyung PAIK
;
Kum Bae KIM
;
Chul Ju HAN
;
Sang Bum KIM
Author Information
1. Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences, Seoul, Korea. mskim@kirams.re.kr
- Publication Type:Original Article
- Keywords:
Radiosurgery;
Cholangiocarcinoma
- MeSH:
Cholangiocarcinoma*;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Multivariate Analysis;
Radiosurgery*;
Recurrence;
Retrospective Studies;
Survival Rate;
Tumor Burden
- From:Radiation Oncology Journal
2014;32(3):163-169
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To report the results of stereotactic body radiotherapy (SBRT) for unresectable primary or recurrent cholangiocarcinoma. MATERIALS AND METHODS: From January 2005 through August 2013, 58 patients with unresectable primary (n = 28) or recurrent (n = 30) cholangiocarcinoma treated by SBRT were retrospectively analyzed. The median prescribed dose was 45 Gy in 3 fractions (range, 15 to 60 Gy in 1-5 fractions). Patients were treated by SBRT only (n = 53) or EBRT + SBRT boost (n = 5). The median tumor volume was 40 mL (range, 5 to 1,287 mL). RESULTS: The median follow-up duration was 10 months (range, 1 to 97 months). The 1-year, 2-year overall survival rates, and median survival were 45%, 20%, and 10 months, respectively. The median survival for primary group and recurrent group were 5 and 13 months, respectively. Local control rate at 1-year and 2-year were 85% and 72%, respectively. Disease progression-free survival rates at 1-year and 2-year were 26% and 23%, respectively. In univariate analysis, ECOG performance score (0-1 vs. 2-3), treatment volume (<50 vs. > or =50 mL), and pre-SBRT CEA level (<5 vs. > or =5 ng/mL) were significant in overall survival rate. In multivariate analysis, ECOG score (p = 0.037) and tumor volume (p = 0.030) were statistically significant. In the recurrent tumor group, patients with >12 months interval from surgery to recurrence showed statistically significant higher overall survival rate than those with < or =12 months (p = 0.026). Six patients (10%) experienced > or =grade 3 complications. CONCLUSION: SBRT can be considered as an effective local modality for unresectable primary or recurrent cholangiocarcinoma.
